Is frequent dosing with ecstasy a risky business for dopamine-containing neurons?

Trends in Pharmacological Sciences

Volumn 24, Issue 6, 2003, Pages 272-274

  O'Shea, Esther ^a   Colado, M Isabel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE;

BRAIN NERVE CELL; BRAIN TEMPERATURE; DOPAMINERGIC NERVE CELL; HUMAN; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STRIATONIGRAL DEGENERATION;

EID: 0038579296     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00133-0     Document Type: Short Survey

References (23)

1. Ricaurte G.A., et al. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ('ecstasy'). Science. 297:2002;2260-2263.
2. Ricaurte G.A., et al. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. J. Am. Med. Assoc. 260:1988;51-55.
3. Ricaurte G.A., et al. Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J. Pharmacol. Exp. Ther. 261:1992;616-622.
4. Hatzidimitriou G., et al. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3, 4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J. Neurosci. 19:1999;5096-5107.
5. Dafters R.I. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol. Behav. 58:1995;877-882.
6. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 18:1998;5086-5094.
7. O'Shea E., et al. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology. 37:1998;919-926.
8. Stitt J.T., Hardy J.D. Thermoregulation in the squirrel monkey (Saimiri sciureus). J. Appl. Physiol. 31:1971;48-54.
9. Ricaurte G.A., et al. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 446:1988;165-168.
10. Yuan J., et al. Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J. Neurochem. 80:2002;960-969.
11. Insel T.R., et al. 3,4-Methylenedioxymethamphetamine ('ecstasy') selectively destroys brain serotonin terminals in rhesus monkeys. J. Pharmacol. Exp. Ther. 249:1989;713-720.
12. Kleven M.S., et al. Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys. Brain Res. 488:1989;121-125.
13. Colado M.I., et al. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol. 121:1997;889-900.
14. Colado M.I., et al. A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br. J. Pharmacol. 121:1997;827-833.
15. Camarero J., et al. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J. Neurochem. 81:2002;961-972.
16. Globus M.Y., et al. Detection of free radical activity during transient global ischemia and recirculation: effects of intraischemic brain temperature modulation. J. Neurochem. 65:1995;1250-1256.
17. Colado M.I., et al. In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology. 38:1999;307-314.
18. Sanchez V., et al. Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology. 44:2003;449-461.
19. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm. 38:1976;277-301.
20. Bezard E., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21:2001;6853-6861.
21. Parrott A.C. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol. 16:2001;557-577.
22. Parrott A.C., et al. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum. Psychopharmacol. 17:2002;309-312.
23. Mordenti J., Chappell W.R. The use of interspecies scaling in toxicokinetics. Yacobi A., et al. Toxicokinetics and New Drug Development. 1989;42-96 Pergamon Press.